CA3210064A1 - Formulations - Google Patents
Formulations Download PDFInfo
- Publication number
- CA3210064A1 CA3210064A1 CA3210064A CA3210064A CA3210064A1 CA 3210064 A1 CA3210064 A1 CA 3210064A1 CA 3210064 A CA3210064 A CA 3210064A CA 3210064 A CA3210064 A CA 3210064A CA 3210064 A1 CA3210064 A1 CA 3210064A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- formulation
- pilocarpine
- produced
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142889P | 2021-01-28 | 2021-01-28 | |
| US63/142,889 | 2021-01-28 | ||
| PCT/US2022/014317 WO2022165178A1 (en) | 2021-01-28 | 2022-01-28 | Formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3210064A1 true CA3210064A1 (en) | 2022-08-04 |
Family
ID=82494246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3210064A Pending CA3210064A1 (en) | 2021-01-28 | 2022-01-28 | Formulations |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11872213B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4284362A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024505517A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022212108A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3210064A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022165178A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220160668A1 (en) | 2020-11-23 | 2022-05-26 | Sight Sciences, Inc. | Formulations and methods for treating conditions of the eye |
| US11872213B2 (en) | 2021-01-28 | 2024-01-16 | Glaukos Corporation | Formulations |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5422116A (en) * | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
| ES2752008T3 (es) * | 2009-10-30 | 2020-04-02 | Intratus Inc | Métodos y composiciones para la liberación sostenida de fármacos |
| US9421199B2 (en) * | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| US11052094B2 (en) * | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
| US20190262290A1 (en) * | 2016-10-12 | 2019-08-29 | Ps Therapies Ltd | Drug vehicle compositions and methods of use thereof |
| CN110996904A (zh) * | 2017-05-19 | 2020-04-10 | 奥古根有限公司 | 眼用组合物及使用方法 |
| JP6946575B2 (ja) * | 2018-04-24 | 2021-10-06 | アラーガン、インコーポレイテッドAllergan,Incorporated | 眼の状態の治療のためのピロカルピン塩酸塩の使用 |
| US11872213B2 (en) | 2021-01-28 | 2024-01-16 | Glaukos Corporation | Formulations |
| WO2024026365A1 (en) * | 2022-07-26 | 2024-02-01 | Glaukos Corporation | Ophthalmic topical cream formulations and uses thereof |
-
2022
- 2022-01-28 US US17/587,510 patent/US11872213B2/en active Active
- 2022-01-28 JP JP2023545783A patent/JP2024505517A/ja active Pending
- 2022-01-28 WO PCT/US2022/014317 patent/WO2022165178A1/en not_active Ceased
- 2022-01-28 AU AU2022212108A patent/AU2022212108A1/en active Pending
- 2022-01-28 CA CA3210064A patent/CA3210064A1/en active Pending
- 2022-01-28 EP EP22746694.3A patent/EP4284362A4/en active Pending
-
2023
- 2023-12-05 US US18/529,306 patent/US12533344B2/en active Active
-
2025
- 2025-12-30 US US19/436,767 patent/US20260124179A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220233506A1 (en) | 2022-07-28 |
| WO2022165178A1 (en) | 2022-08-04 |
| EP4284362A4 (en) | 2024-12-25 |
| US20260124179A1 (en) | 2026-05-07 |
| US11872213B2 (en) | 2024-01-16 |
| WO2022165178A9 (en) | 2022-10-13 |
| US20240115551A1 (en) | 2024-04-11 |
| AU2022212108A1 (en) | 2023-08-17 |
| AU2022212108A9 (en) | 2024-05-09 |
| US12533344B2 (en) | 2026-01-27 |
| JP2024505517A (ja) | 2024-02-06 |
| EP4284362A1 (en) | 2023-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260124179A1 (en) | Formulations | |
| US20250381215A1 (en) | High elasticity hyaluronan compositions and methods of use thereof | |
| Cheng et al. | Sustained delivery of latanoprost by thermosensitive chitosan–gelatin-based hydrogel for controlling ocular hypertension | |
| Nanjawade et al. | RETRACTED: In situ-forming hydrogels for sustained ophthalmic drug delivery | |
| CA2848156A1 (en) | Ophthalmic compositions comprising prostaglandin f2 alpha derivatives and hyaluronic acid | |
| CN104906580A (zh) | 无刺激性眼科聚维酮碘组合物 | |
| WO2016016908A1 (en) | Method of increasing bioavailability and/or prolonging ophthalmic action of a drug | |
| EP2249765B1 (en) | Dapsone to treat rosacea | |
| Rubenicia et al. | Intraocular pressure reduction effect of 0.005% latanoprost eye drops in a hyaluronic acid-chitosan nanoparticle drug delivery system in albino rabbits | |
| CN101977630B (zh) | 眼药组合物 | |
| US20190262290A1 (en) | Drug vehicle compositions and methods of use thereof | |
| CN115487139B (zh) | 一种葛根素结冷胶离子型原位凝胶滴眼液及制备方法 | |
| CA2851492A1 (en) | Ophthalmic gel compositions | |
| Huang et al. | Bimatoprost ophthalmic solution | |
| US12576126B2 (en) | Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof | |
| Wilson | Ophthalmic Formulation | |
| CN102018656A (zh) | 含有效成分拉坦前列素的眼用凝胶剂及其制备方法 | |
| KR100938233B1 (ko) | 프로스타글란딘계 점안용 조성물과 그의 제조 방법 | |
| CN103202833A (zh) | 一种奥洛他定或其盐的药用组合物及其制备方法 | |
| RU2806029C2 (ru) | Композиции, обеспечивающие повышенный комфорт для глаз | |
| Mundada | Update on Polymers for Ocular Drug Delivery | |
| HK40128453A (en) | Compositions and methods for the treatment of presbyopia | |
| WO2016122169A1 (ko) | 뉴레귤린을 포함하는 상처 또는 안구건조증의 치료용 약학 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241230 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241230 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241230 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251215 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251215 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251215 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251219 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251231 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251231 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260210 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260210 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260210 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260211 |